|Bid||4.8200 x 1000|
|Ask||4.8300 x 1300|
|Day's Range||4.6000 - 4.8600|
|52 Week Range||3.8800 - 40.2200|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors need to pay close attention to Aprea (APRE) stock based on the movements in the options market lately.
Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.
Aprea Therapeutics Inc (NASDAQ: APRE) has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remission (CR) rate. The trial is assessing eprenetapopt with venetoclax and azacitidine in patients with TP53 mutant AML. In 30 patients who were evaluable for efficacy at the time of the analysis, the CR rate was 37%. The composite rate of CR plus CR with incomplete hematologic recovery (CRi), CR/CRi